ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rocbrutinib

Also written as “Rocbrutinib”, “LP-168 tablet” and “LP-168”.

Its studies are mostly in Lymphoma, Mantle-Cell · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Sclerosis, Relapsing-Remitting · Waldenstrom Macroglobulinemia, led by 2 companies.

Drug pageRocbrutinib: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 13, 202615 company-led studies, 12 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lupeng Pharmaceuticalits history only1411 open or runningphase 3since Jan 13, 2026Feb 22, 2021Mar 31, 2027phase 1 · NCT04993690
Hansoh Pharmaceutical Group11 open or runningphase 2since Mar 4, 2025Mar 4, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2023Named rocbrutinibINNProposed as its International Nonproprietary Name in WHO's List 129 · before, LP-168
  2. Mar 4, 2025First study: phase 2 study in Chronic UrticariaFirst studyNCT06864507 · 150 planned · China

TargetBeta

BTK →read by rule
“An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

The one study Hansoh Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06864507Chronic Urticaria · China2Not yet recruitingSep 27, 2026150

How it is read

Names in the registry

  • “Rocbrutinib”, 7 entries
  • “LP-168 tablet”, 3 entries
  • “LP-168”, 2 entries
  • “Lacutoclax+Rocbrutinib”, 1 entry
  • “Rocbrutinib tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.